TrialDiabetes, obesity & metabolism2022

Comparing a daily versus weekly titration algorithm in people with type 2 diabetes switching from basal insulin to iGlarLixi in the LixiLan ONE CAN randomized trial.

Irene Hramiak et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.